Big money is funding a new class of diagnostics that may predict our disease long before it is expressed. While reimbursement presents traditional barriers to those on the bleeding edge, the value of the predictive indicator data these companies are amassing may dwarf the need for it. Talk with leaders about how diagnostics are driving new insights and may be the next AI dark horse.
Host: Sue Siegel, former Chief Innovation Officer & CEO, GE Ventures, GE
Chad Robins, Co-Founder & CEO, Adaptive Biotechnologies
Mike Pellini, MD, Managing Partner, Section 32; Chairman, Foundation Medicine
Kim Popovits, President & CEO, Genomic Health
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare Full bio ›
Mr. Robins is Adaptive’s Chief Executive Officer and Co-founder. He has held executive-level positions in real estate, investment banking, private equity and medical technology. In 2012, Mr. Robins was a “40 Under 40” Seattle Leaders honoree. In 2015, he and his brother, Harlan Robins, were honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Mr. Robins was a finalist Full bio ›
Sue Siegel has driven game-changing ideas and powered companies that advance industries and improve lives for more than three decades. With vast experience across industries, she is on the forefront of the Fourth Industrial Revolution and is helping companies identify and seize transformative digital opportunities. As GE’s Chief Innovation Officer and CEO of GE Ventures, Sue led the development and acceleration of innovatio Full bio ›